CD4 and hepatitis A virus infection: The 50th, 75th and 90th percentiles of time-to-hepatitis in CMV-IgG+ patients were 24, 52 and 84 days, respectively; therefore, we treated four CMV IgG+ CD4+ TEM≥16% patients receiving αPD-1/αCTLA-4 therapy with prophylactic valganciclovir for between 4 and 23 weeks (Fig. 9a).